Clinical trials: Post Covid-19
- Condition Post Covid-19
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
COVID-19 Pneumonia
Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity and safety of the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (Vero cells) in patients aged 60 years or older with hypertension and/or diabetes…
- Trial name
- NCT05065879
- Testing
- COVAX
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104437
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 3 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in…
- Trial name
- NCT05895110
- Testing
- Recombinant Novel Coronavirus vaccine (CHO Cells)
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster…
- Trial name
- NCT05875701
- Testing
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novavax
Covid19
Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]
The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is…
- Trial name
- NCT05060666
- Testing
- Ivermectin
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Infectopharm Arzneimittel GmbH
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics)
In late December 2019, a new coronavirus strain emerged causing coronavirus disease 2019 (COVID19). Since then, COVID19 has become a global pandemic outbreak being declared a "public health emergency of international concern" by…
- Trial name
- NCT04466644
- Testing
- ELISA, RT-PCR
- Where
- 2 sites in United States
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Igenomix
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Long COVID
Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19
The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the…
- Trial name
- NCT06311435
- Testing
- RNA Biomarker Blood Test
- Where
- 3 sites in United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- MaxWell Clinic, PLC
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
covid19
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable…
- Trial name
- NCT04435314
- Testing
- Nitazoxanide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Covid19, SARS-COV-2 Infection
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
- Trial name
- NCT04721535
- Testing
- DWJ1248
- Where
- South Korea
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine…
- Trial name
- COVID-19 (NCT05096832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 18 sites in Malaysia, Pakistan
- Volunteers
- 10,381 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104333
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 5 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Coronavirus Disease 2019
Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Popular topic: Clinical study on immunogenicity and safety evaluation of sequentially enhanced immunity with recombinant Novel Coronavirus vaccine (CHO cells) Research purpose:Main purpose:To evaluate the immunogenicity of…
- Trial name
- NCT05089045
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac
Study objectives: To evaluate the immunogenicity and immunity persistence and safety of recombinant novel coronavirus vaccine (CHO cells) after booster immunization in populations vaccinated with two doses of marketed novel…
- Trial name
- NCT05205096
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.